Dafne A. Quixabeira
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.
Journal: Journal for immunotherapy of cancer
Published: July 27, 2026
Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 01, 2025
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models.
Journal: Cancer immunology, immunotherapy : CII
Published: January 28, 2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.
Journal: Journal for immunotherapy of cancer
Published: January 09, 2025
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma.
Journal: Molecular therapy. Oncology
Published: November 29, 2024
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.
Journal: Cancer gene therapy
Published: November 27, 2024
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.
Journal: Journal of experimental & clinical cancer research : CR
Published: September 11, 2024
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.
Journal: Cell reports. Medicine
Published: August 29, 2024
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 19, 2024
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 10, 2023
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 17, 2023
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
Journal: Oncoimmunology
Published: August 07, 2023
Last Updated: 09/26/2026